美国长期护理机构2011-2014年抗精神病药与心境稳定剂处方趋势
该研究基于2011-2014年20% Medicare样本的重复横断面分析,纳入长期护理机构中具有Part D覆盖的按服务收费受益人(n=562,485),并二次分析抑郁症或双相障碍患者(n=139,071)。结果显示抗精神病药调整预测概率从0.120降至0.100,心境稳定剂从0.140升至0.185;在抑郁症或双相障碍患者中,抗精神病药从0.081升至0.087,心境稳定剂从0.193升至0.251。结论指出抗精神病药与心境稳定剂治疗可能性在抑郁症或双相障碍住院者中并未下降,心境稳定剂增长广泛且主要由加巴喷丁驱动。
要点
- 长期护理机构中抗精神病药调整预测概率从0.120降至0.100,痴呆患者下降幅度更大。
- 心境稳定剂调整预测概率从0.140升至0.185,无痴呆者增长略大。
- 抑郁症或双相障碍患者中抗精神病药从0.081升至0.087,心境稳定剂从0.193升至0.251。
核心结论
- 抗精神病药与心境稳定剂治疗可能性在抑郁症或双相障碍长期护理住院者中并未下降。
- 心境稳定剂使用增长广泛,且主要由加巴喷丁处方增长驱动。
研究设计与样本
- 重复横断面分析,使用2011-2014年20% Medicare样本。
- 纳入长期护理机构中具有Part D覆盖的按服务收费Medicare受益人(n=562,485)。
- 二次分析限于抑郁症或双相障碍患者(n=139,071)。
主要发现
- 抗精神病药调整预测概率从2011年0.120(95%CI 0.119-0.121)降至2014年0.100(95%CI 0.099-0.101;P<.001)。
- 抗精神病药使用在所有年龄、性别和种族/族裔组均下降,痴呆患者下降幅度更大(P<.001)。
- 心境稳定剂调整预测概率从0.140(95%CI 0.139-0.141)升至0.185(95%CI 0.184-0.186),无痴呆者增长略大(P<.001)。
- 抑郁症或双相障碍患者中抗精神病药调整预测概率从0.081(95%CI 0.079-0.082)升至0.087(95%CI 0.085-0.088;P<.001)。
- 抑郁症或双相障碍患者中心境稳定剂调整预测概率从0.193(95%CI 0.190-0.196)升至0.251(95%CI 0.248-0.253;P<.001)。
关键数值与推荐
- 喹硫平是最常处方的抗精神病药。
- 加巴喷丁是最常处方的心境稳定剂,2014年底占接受心境稳定剂者的70.5%。
临床怎么用
- 在长期护理机构中需关注抗精神病药与心境稳定剂处方趋势,尤其对抑郁症或双相障碍患者。
- 加巴喷丁作为心境稳定剂使用增长显著,临床应评估其处方合理性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Centers for Medicare and Medicaid Services' National Partnership to Improve Dementia Care in Nursing Homes focuses on but is not limited to long-term care (LTC) residents with dementia; the potential impact on residents with other diagnoses is unclear. We sought to determine whether resident subpopulations experienced changes in antipsychotic and mood stabilizer prescribing. DESIGN: Repeated cross-sectional analysis of a 20% Medicare sample, 2011-2014. SETTING AND PARTICIPANT: Fee-for-service Medicare beneficiaries with Part D coverage in LTC (n = 562,485) and a secondary analysis limited to persons with depression or bipolar disorder (n = 139,071). METHODS: Main outcome was quarterly predicted probability of treatment with an antipsychotic or mood stabilizer. RESULTS: From 2011 to 2014, the adjusted predicted probability (APP) of antipsychotic treatment fell from 0.120 [95% confidence interval (CI) 0.119-0.121] to 0.100 (95% CI 0.099-0.101; P < .001). Use decreased for all age, sex, and racial/ethnic groups; the decline was larger for persons with dementia (P < .001). The APP of mood stabilizer use grew from 0.140 (95% CI 0.139-0.141) to 0.185 (95% CI 0.184-0.186), growth slightly larger among persons without dementia (P < .001). Among persons with depression or bipolar disorder, the APP of antipsychotic treatment increased from 0.081 (95% CI 0.079-0.082) to 0.087 (95% CI 0.085-0.088; P < .001); APP of mood stabilizer treatment grew more, from 0.193 (95% CI 0.190-0.196) to 0.251 (0.248-0.253; P < .001). Quetiapine was the most commonly prescribed antipsychotic. The most widely prescribed mood stabilizer was gabapentin, prescribed to 70.5% of those who received a mood stabilizer by the end of 2014. CONCLUSIONS AND IMPLICATIONS: The likelihood of antipsychotic and mood stabilizer treatment did not decline for residents with depression or bipolar disorder, for whom such prescribing may be appropriate but who were not excluded from the Partnership's antipsychotic quality measure. Growth in mood stabilizer use was widespread, and largely driven by growth in gabapentin prescribing.
引用
- Gerlach LB, Kales HC, Kim HM, et al. Trends in Antipsychotic and Mood Stabilizer Prescribing in Long-Term Care in the U.S.: 2011-2014. J Am Med Dir Assoc. 2020. PMID: 32693995. doi:10.1016/j.jamda.2020.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。